{
    "nct_id": "NCT05308654",
    "official_title": "First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status <= 1.\n* Laboratory values meeting the criteria outlined in the protocol.\n* Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria.\n* Has measurable disease at screening as defined in the protocol.\n* Locally documented or centrally determined t(11;14) positive status and/or centrally determined BCL2high status. Note: If local testing for t(11;14) is discordant with central testing for t(11;14) status, a detailed review of central and local results for t(11;14) status is required to ensure the participants' safety.\n* Part 1 and Part 2, Arm 1 Only: Refractory to or intolerant of all established MM therapies that are known to provide clinical benefit and are triple class exposed to a proteasome inhibitors (PI), an Immunomodulatory drugs (IMID), and an anti-CD38 monoclonal antibody in previous line(s) of therapy.\n* Part 2, Arms 2 and 3 Only: Received 1 to 3 prior lines of therapy, including a PI or an IMiD.\n* Part 1 only: Permitted to be venetoclax or BCL-2 inhibitor exposed in previous lines of therapy.\n* Life expectancy >= 12 weeks.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically relevant or significant Electrocardiogram (ECG) abnormalities as outlined in the protocol.\n* Part 2 only: Previous treatment with venetoclax or BCL-2 inhibitor.\n* Part 2, Arms 2 and 3 only: Prior daratumumab or other anti-CD38 therapy exposure that meets any of the criteria outlined in the protocol.",
    "miscellaneous_criteria": ""
}